VERTEX PHARMACEUTICALS INC / MA
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans for the sale of our securities adopted by our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) during the third quarter of 2025, and one from the second quarter of 2025 that was previously not disclosed, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
| Name and Title | Date of Adoption of Trading Plan | Scheduled Expiration Date of Trading Plan (1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|
| Carmen BozicEVP, Global Medicines Development and Medical Affairs, Chief Medical Officer | 5/30/2025 | 11/21/2025 | 19,404 |
| Kristen AmbroseSVP, Chief Accounting Officer | 8/08/2025 | 8/03/2026 | 7,539(2) |
| Jeffrey LeidenExecutive Chairman | 8/06/2025 | 1/21/2026 | 144,644 |
| E. Morrow "Morrey" Atkinson, IIIEVP, Chief Technical Operations Officer, Head of Biopharmaceuitcal Sciences and Manufacturing Operations | 8/11/2025 | 4/30/2026 | 12,709(2) |
| Ourania "Nia" TatsisEVP, Chief Regulatory and Quality Officer | 8/21/2025 | 7/31/2026 | 24,301(2) |
| (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan. | |||
| (2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.